Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marlon Graf

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Clinical Transplantation|January 5, 2023
Gaining consensus around patient risk groups and prognostic profiles to guide CMV management among patients with solid organ transplant: Insights from a Delphi panel with SOT expertsPriti Pednekar, Marlon Graf, Rifat Tuly, et al.
Journal of Managed Care & Specialty Pharmacy|April 12, 2021
Understanding the evolution of coverage policies for prophylaxis treatments of hemophilia A without inhibitors: a payer Delphi panelMarlon Graf, Rifat Tuly, Carolyn Harley, et al.
Transplantation Proceedings|February 18, 2024
Gaining Consensus Around Patient Risk Groups and Prognostic Profiles to Guide CMV Management Among Patients With Allogeneic Hematopoietic Stem Cell Transplant: Insights From a Delphi Panel With Hematopoietic Stem Cell Transplant ExpertsMarlon Graf, Rifat Tuly, Priti Pednekar, et al.
Journal of Medical Economics|August 15, 2022
Estimating the impact of biosimilar entry on prices and expenditures in rheumatoid arthritis: a case study of targeted immune modulatorsErvant J Maksabedian Hernandez, Marlon Graf, Alexandria Portelli, et al.
American Journal of Hematology|May 23, 2022
Value of a cure for sickle cell disease in reducing economic disparitiesMarlon Graf, Rifat Tuly, Meghan Gallagher, et al.
Journal of Blood Medicine|October 28, 2021
A Delphi Consensus Approach for Difficult-to-Treat Patients with Severe Hemophilia A without InhibitorsSreenivas P Veeranki, Priti Pednekar, Marlon Graf, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 25, 2025
Implementing the Generalized Risk-Adjusted Cost-Effectiveness Model for Sickle Cell Disease: A Case StudyMarlon Graf, Joris Kleintjens, Md Tahsin Hasan, et al.
The American Journal of Managed Care|January 3, 2024
Generalized cost-effectiveness analysis to assess treatment value in hepatitis CJacquelyn W Chou, Marlon Graf, Oliver Díaz Espinosa, et al.
Journal of Managed Care & Specialty Pharmacy|October 15, 2021
Schizophrenia population health management: perspectives of and lessons learned from population health decision makersMeaghan Roach, Dee Lin, Marlon Graf, et al.
Heliyon|September 9, 2024
Physician preferences for treatment of low-density lipoprotein cholesterol among patients with atherosclerotic cardiovascular disease (ASCVD)-A discrete choice experimentMarlon Graf, Amit V Khera, Suepattra G May, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Clinical Transplantation|January 5, 2023
Gaining consensus around patient risk groups and prognostic profiles to guide CMV management among patients with solid organ transplant: Insights from a Delphi panel with SOT expertsPriti Pednekar, Marlon Graf, Rifat Tuly, et al.
Journal of Managed Care & Specialty Pharmacy|April 12, 2021
Understanding the evolution of coverage policies for prophylaxis treatments of hemophilia A without inhibitors: a payer Delphi panelMarlon Graf, Rifat Tuly, Carolyn Harley, et al.
Transplantation Proceedings|February 18, 2024
Gaining Consensus Around Patient Risk Groups and Prognostic Profiles to Guide CMV Management Among Patients With Allogeneic Hematopoietic Stem Cell Transplant: Insights From a Delphi Panel With Hematopoietic Stem Cell Transplant ExpertsMarlon Graf, Rifat Tuly, Priti Pednekar, et al.
Journal of Medical Economics|August 15, 2022
Estimating the impact of biosimilar entry on prices and expenditures in rheumatoid arthritis: a case study of targeted immune modulatorsErvant J Maksabedian Hernandez, Marlon Graf, Alexandria Portelli, et al.
American Journal of Hematology|May 23, 2022
Value of a cure for sickle cell disease in reducing economic disparitiesMarlon Graf, Rifat Tuly, Meghan Gallagher, et al.
Journal of Blood Medicine|October 28, 2021
A Delphi Consensus Approach for Difficult-to-Treat Patients with Severe Hemophilia A without InhibitorsSreenivas P Veeranki, Priti Pednekar, Marlon Graf, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 25, 2025
Implementing the Generalized Risk-Adjusted Cost-Effectiveness Model for Sickle Cell Disease: A Case StudyMarlon Graf, Joris Kleintjens, Md Tahsin Hasan, et al.
The American Journal of Managed Care|January 3, 2024
Generalized cost-effectiveness analysis to assess treatment value in hepatitis CJacquelyn W Chou, Marlon Graf, Oliver Díaz Espinosa, et al.
Journal of Managed Care & Specialty Pharmacy|October 15, 2021
Schizophrenia population health management: perspectives of and lessons learned from population health decision makersMeaghan Roach, Dee Lin, Marlon Graf, et al.
Heliyon|September 9, 2024
Physician preferences for treatment of low-density lipoprotein cholesterol among patients with atherosclerotic cardiovascular disease (ASCVD)-A discrete choice experimentMarlon Graf, Amit V Khera, Suepattra G May, et al.
Pageof 2